Home > Division of Hematological Malignancy
Division of Hematological Malignancy
Despite great progress in curing leukemia and malignant tumor, survival after relapse remains poor. The essential cause of the relapse following conventional therapy is a remaining population of drug-resistant cancer stem cells. Thus, selective targeting of LSCs is a promising strategy for preventing relapse. In our division, we investigate molecular mechanisms for epigenetic and metabolic regulations that are essential for maintenance of cancer tissues, especially cancer stem cells, to develop novel cancer therapy.